TY - JOUR
T1 - Mouse models of lipodystrophy
T2 - Key reagents for the understanding of the metabolic syndrome
AU - Asterholm, Ingrid Wernstedt
AU - Halberg, Nils
AU - Scherer, Philipp E.
N1 - Funding Information:
The authors were supported by NIH grants R01-DK55758, R24-DK071030-01, R01-CA112023 and R21DK075887 (PES). IWA was also supported with a fellowship from the Throne-Holst Foundation and the Swedish Research Council (2006-3931), and NH is supported by a stipend from the Faculty of Health Science of the University of Copenhagen.
PY - 2007
Y1 - 2007
N2 - Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.
AB - Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.
UR - http://www.scopus.com/inward/record.url?scp=37349063135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37349063135&partnerID=8YFLogxK
U2 - 10.1016/j.ddmod.2007.10.003
DO - 10.1016/j.ddmod.2007.10.003
M3 - Review article
C2 - 18193096
AN - SCOPUS:37349063135
SN - 1740-6757
VL - 4
SP - 17
EP - 24
JO - Drug Discovery Today: Disease Models
JF - Drug Discovery Today: Disease Models
IS - 1
ER -